NCT04631055已完成不适用
A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Intracranial Drug-coated Balloon Catheters in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 3
- 主要终点
- Primary efficacy endpoint: Angiographic restenosis of the target lesion
研究概览
简要总结
The purpose of the RCT trial is to determine whether DCB is not inferior to stent in treating intracranial stenosis.
详细描述
This trial is a prospective, multi-center, 1:1 randomized using paclitaxel coated balloon versus stent to treat intracranial stenosis of 70-99% degree. And primary endpoint is angiographic restenosis at 6 months post-procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 80 years of age;
- •Patients with symptomatic intracranial atherosclerotic stenosis;
- •Patients with intracranial arterial de novo stenosis confirmed by digital subtraction angiography (DSA);
- •Confirmed by DSA，the diameter of the target vessel is between 2.5mm-4.5mm ; according to WASID method, the degree of stenosis of the target lesion is 70%-99%;
- •Baseline mRS score ≤2;
- •Voluntarily participate in this study and sign the informed consent form.
排除标准
- •Patients with stroke within 2 weeks before procedure;
- •Patients with stroke caused by perforating artery occlusion;
- •Any history of brain parenchymal or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days;
- •Those who have received thrombolysis within 24 hours before procedure;
- •Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline);
- •The vascular path showed in angiography is so tortuous that it is difficult to advance catheters to the target lesion or retrieve;
- •Lesions that investigators believe are not suitable for stenting;
- •Patients with thrombus in target vessel;
- •In addition to the target lesion, there are still other de novo lesion or ISR lesion with more than 70% diameter stenosis in intracranial arteries that need to be treated at the same time;
- •After endovascular treatment of the target lesion, there is still a stenosis of more than 50% in the main blood supplying artery or an obstructive lesion in the distal vessel of target lesion;
- •Major surgery (including open femoral artery, aortic or carotid artery surgery) within the past 30 days or planned within 90 days;
- •Patients with renal artery, iliac artery, and coronary artery requiring simultaneous intervention;
- •Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation;
- •Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, moya-moya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any Other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected Vasospasm, suspicious embolism recanalization, etc.;
- •Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;
- •Patients with myocardial infarction within 6 weeks before procedure;
- •Those who cannot tolerate general anesthesia due to insufficiency of important organs such as heart and lungs;
- •Patients with known severe hepatic and renal dysfunction;
- •Patients with hemoglobin<100g/L, platelet count<100×1,000,000,000/L, INR>1.5 or there are uncorrectable factors leading to bleeding(if there are multiple checks, the last one shall prevail);
- •Patients who cannot receive dual antiplatelet therapy due to existing diseases or are tolerant to dual antiplatelet therapy confirmed by relevant test;
- •Patients with known severe allergies or contraindications to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs;
- •Current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg);
- •Life expectancy <1 year;
- •Pregnant or lactating women;
- •Patients who cannot complete the follow-up due to cognitive, emotional or mental illness;
- •Patients who are participating in other drug/device clinical trials and have not completed all follow-ups required by the programmer;
- •According to the judgement of the investigator, other situations that are not suitable for enrollment.
结局指标
主要结局
Primary efficacy endpoint: Angiographic restenosis of the target lesion
时间窗: 6 months post-procedure
Definition of Restenosis: 1. Post-procedural residual stenosis \< 30% of target lesion occurs \>50% stenosis within the treated segment at 6 months angiographic follow-up. 2. Post-procedural residual stenosis 30-50% of target lesion occurs \>20% absolute luminal loss within the treated segment at 6 months angiographic follow-up.
Primary safety endpoint: Target vessel stroke or death event
时间窗: within 30 days post-procedure
Stroke (Hemorrhagic stroke and ischemic stroke) or death related to target vessels within 30 days postoperatively.
次要结局
- Cerebral parenchyma hemorrhage, subarachnoid hemorrhage or intraventricular hemorrhage events(between 31 days and 6 months post-procedure)
- Transient ischemic attack event(at 6 months post-procedure)
- Device success rate(during procedure)
- Target vessel ischemia stroke event(between 31 days and 6 months post-procedure)
- Target vessel death event(between 31 days and 6 months post-procedure)
- National Institutes of Health Stroke Scale score(at 6 months post-procedure)
- Modified Rankin Scale score(at 6 months post-procedure)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Evaluating the Safety and Efficacy of the Maurora® DES in ICASIntracranial ArteriosclerosisStroke (CVA) or TIANCT05719883Beijing Tiantan Hospital156
已完成
不适用
AcoArt VI / Vertebral Artery Ostium Stenosis in ChinaIschemic StrokeTransient Ischemic AttackNCT03910166Acotec Scientific Co., Ltd180
进行中（未招募）
不适用
Drug-Coated Balloon in Patients With High Bleeding RiskCoronary Artery DiseaseNCT05221931Samsung Medical Center1,359
尚未招募
不适用
Comparative Clinical Study of Drug-coating Balloon Strategy and Drug-eluting Stent StrategyCoronary Artery DiseaseNCT04842838Peking University Third Hospital1,000
尚未招募
2 期
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractAllergy to House Dust MiteAllergic RhinoconjunctivitisAllergic AsthmaAllergic RhinitisNCT05641272Inmunotek S.L.90